Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jul 7;17(8):1874–1888. doi: 10.1016/j.stemcr.2022.06.003

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Author(s)

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Preliminary drug screening of patient-derived FLC organoids

(A) Correlation plots of screening ∼650 compounds against 6 M₂ organoids performed twice (day 1 and day 2), each in singlet (R² = 0.31; x axis, normalized %survival inhibition on day 1; y axis, normalized %survival inhibition on day 2. Blue dot, positive control (20 μM chaetocin); red dots, negative control (DMSO); gray dots, compounds tested. Compounds in the top right quandrant killed at least 50% 6 M₂ organoids in both experiments.

(B) Normalized percent inhibition of some of the most efficacious compounds against FLC organoids, HepG2 cells (from a 15-year-old Caucasian male who had a well-differentiated hepatocellular carcinoma), MRC5 (fibroblast cell line from lung), and SK-N-SH (neuroblastoma).